BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mrna stabilization in breast cancer cells

Oncotarget

Volumn 3, Issue 3, 2012, Pages 299-313

  Shimizu, Yoshiko ^a   Mullins, Nicole ^a   Blanchard, Zannel ^a   ElShamy, Wael M ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Brca1 iris; BRCA1 p220; Breast cancer; Invasion metastasis; RNA stability; Survival

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; ISOPROTEIN; MESSENGER RNA; SMALL INTERFERING RNA;

ARTICLE; BREAST TUMOR; CARCINOMA; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; RNA STABILITY; TIME; TUMOR CELL CULTURE; UPREGULATION;

BASE SEQUENCE; BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; RNA STABILITY; RNA, MESSENGER; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84864395208     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.462     Document Type: Article

References (51)

1. Billack B, Monteiro A. BRCA1 in breast and ovarian cancer predisposition. Cancer Lett 2005; 227: 1-7.
2. Rowell S, Newman B, Boyd J, King MC. Inherited predisposition to breast cancer and ovarian cancer. Am J Hum Genet 1994; 55: 861-865.
3. Reis-Filho J, Tutt A. Triple negative tumours: a critical review. Histopathology 2008; 52(1): 108-118.
4. Yang Q, Yoshimura G, Nakamura M, Nakamura Y, Suzuma T, Umemura T, Mori I, Sakurai T, Kakudo K. BRCA1 in non-inherited breast carcinomas. Oncol Rep 2002; 9: 1329-1333.
5. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
6. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006; 25: 5864-5874.
7. Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT Chung JH, Powell SN, Xia F. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol. Cell Biol 2004; 24(2): 708-718.
8. Yarden R, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet 2002; 30(3): 285-289.
9. Ma Y, Fan S, Hu C, Meng Q, Fuqua SA, Pestell RG Tomita YA, Rosen EM. BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Mol. Endocrinol 2010; 24(1): 76-90.
10. Morris J, Solomon E. BRCA1: BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum Mol Genet 2004; 13(8): 807-817.
11. Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, Powell SN, Yang Q. Negative Regulation of AKT Activation by BRCA1. Cancer Res 2008; 68(24): 10040-10044.
12. Fulda S. Tumor resistance to apoptosis. Int. J. Cancer 2009; 124(3): 511-515.
13. Giménez-Bonafé P, Tortosa A, Pérez-Tomás R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 2009; 9(3): 320-340.
14. Mazars R, Spinardi L, BenCheikh M, Simony-Lafontaine J, Jeanteur P, Theillet C. p53 mutations occur in aggressive breast cancer. Cancer Res 1992; 52(14): 3918-3923.
15. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res 2005; 94: 29-86.
16. Nassar A, Sexton D, Cotsonis G, Cohen C. Survivin expression in breast carcinoma: correlation with apoptosis and prognosis. Appl. Immunohistochem. Mol. Morphol 2008; 16(3): 221-226.
17. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002; 59: 1406-1412.
18. Newbury S. Control of mRNA stability in eukaryotes. Biochem Soc Trans 2006; 34(Pt 1): 30-34.
19. Barreau C, Paillard L, Osborne HB. AU-rich elements and associated factors: are there unifying principles? Nucleic Acids Res 2006; 33: 7138-7150.
20. Wang Z, Day N, Trifillis P, Kiledjian M. An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA in vitro. Mol Cell Biol 1999; 19: 4552-4560.
21. Blixall B, Pende A, Wu SC, Port JD. Correlation between intrinsic mRNA stability and the affinity of AUF1 (hnRNP D) and HuR for A+U-rich mRNAs. Mol Cell Biochem 2002; 232: 1-11.
22. Makeyev A, Liebhaber S. The poly(C)-binding proteins: a multiplicity of functions and a search for mechanisms. RNA 2008; 8: 265-278.
23. Lal A, Mazan-Mamczarz K, Kawai T, Yang X, Martindale JL, Gorospe M. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J 2004; 23: 3092-3102.
24. Balmer L, Beveridge D, Jazayeri J, Thomson A, Walker C, Leedman P. Identification of a NovelAU-Rich Element in the 3' Untranslated Region of Epidermal Growth Factor Receptor mRNA That Is the Target for Regulated RNABinding Proteins. Mol Cell Biol 2002; 21: 2070-2084.
25. Brewer G. An A+U-rich element RNA-binding factor regulates c-myc mRNA stability in vitro. Mol Cell Biol 1991; 11: 2460-2466.
26. Shaw G, Kamen A. Conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986; 46: 659-667.
27. Wilson T, Treisman R. Removal of poly(A) and consequent degradation of c-fos mRNA facilitated by 3' AU-rich sequences. Nature 1988; 336: 396-399.
28. Roychoudhury P, Paul RR, Chowdhury R, Chaudhuri K. HnRNP E2 is downregulated in human oral cancer cells and the overexpression of hnRNP E2 induces apoptosis. Mol Carcinog 2007; 46(3): 198-207.
29. Sommer S, Cui Y, Brewer G, Fuqua S. The c-Yes 3'-UTR contains adenine/uridine-rich elements that bind AUF1 and HuR involved in mRNA decay in breast cancer cells. J. Steroid Biochem. Mol Biol 2005; 97(3): 219-229.
30. ElShamy WM, Livingston D. Identification of BRCA1-IRIS, a BRCA1 locus product. Nat Cell Biol 2004; 6(10): 954-967.
31. Nakuci E, Mahner S, Direnzo J, ElShamy WM. BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. Exp Cell Res 2006; 312(16): 3120-3131.
32. Hao L, ElShamy WM. BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR. Int J Cancer 2007; 121(1): 39-46.
33. Chock K, Allison J, ElShamy WM. BRCA1-IRIS overexpression abrogates UV-induced p38MAPK/p53 and promotes proliferation of damaged cells. Oncogene 2010a; 29(38): 5274-5285.
34. Chock K, Allison J, Shimizu Y, ElShamy WM. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Cancer Res 2010b; 70(21): 8782-8791.
35. Gorski J, James C, Quinn J, Stewart G, Staunton K, Buckley N. BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Res Treat 2010; 122(3): 721-731.
36. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli M. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003; 88(8): 1285-1291.
37. Fan W, Jin S, Ong T, HongCheng Z, Fan F, Aniston M, Rajasekara B, Wu M, Zhar Q. BRCA1 regulates GADD45 through its interaction with the Oct1 and CAAT motifs. J Biol Chem 2002; 277: 8061-8067.
38. Yin H, Chao L, Chao J. Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt glycogen synthase kinase-3 and Akt-bad-14-3-3 signaling pathways. J Biol Chem 2005; 280: 8022-8030.
39. Al-Bazz Y, Underwood J, Brown B, Dobson P. Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer. Eur J Cancer 2009; 45(4): 694-704.
40. Quinn J, Kennedy R, Mullan P, Gilmore P, Carty M, Johnston P. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63(19): 6221-6228.
41. Welcsh P, Lee M, Gonzalez-Hernandez R, Black DJ, Mahadevappa M, Swisher EM. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA 2002; 99(11): 7560-7565.
42. Wen J, Li R, Lu Y, Shupnik M. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Oncogene 2009; 28(4): 575-586.
43. Saunus J, French J, Edwards S, Beveridge D, Hatchell E, Wagner S. Posttranscriptional Regulation of the Breast Cancer Susceptibility Gene BRCA1 by the RNA Binding Protein HuR. Cancer Res 2008; 68(22): 9469-9478.
44. Heinonen M, Bono P, Narko K, Chang SH, Lundin J, Joensuu H. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 2005; 65: 2157-2161.
45. Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomäki K, Blomqvist C. Prognostic Role of HuR in Hereditary Breast Cancer. Clin Cancer Res 2007; 13(23): 6959-6963.
46. Thakur S, Nakamura T, Calin G, Russo A, Tamburrino J, Shimizu M. Regulation of BRCA1 transcription by specific single-stranded DNA binding factors. Mol Cell Biol 2003; 23: 3774-3787.
47. Shimizu Y, Luk H, Horio D, Miron P, Griswold M, Iglehart D, Hernandez B, Killeen J, ElShamy WM. BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. Plos One, in press.
48. Kemmis C, Welsh J. Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway. J Cell Biochem 2008; 105(4): 980-988.
49. Kanies C, Smith J, Kis C, Schmidt C, Levy S, Khabar KS, Morrow J, Deane N, Dixon DA, Beauchamp RD. Oncogenic Ras and transforming growth factor-beta synergistically regulate AU-rich element-containing mRNAs during epithelial to mesenchymal transition. Mol Cancer Res 2008; 6(7): 1124-1136.
50. Chen C-Y, Xu N, Shyu A-B. mRNA decay mediated by two distinct AU-rich elements from c-fos and granulocytemacrophage colony-stimulating factor transcripts: different deadenylation kinetics and uncoupling from translation. Mol Cell Biol 1995; 15: 5777-5788.
51. Shyu A-B, Greenberg M, Belasco J. The c-fos mRNA is targeted for rapid decay by two distinct mRNA degradation pathways. Genes Dev 1989; 3: 60-72.